ALGN stock icon

Align Technology
ALGN

$271.28
2.21%
 

About: Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

Employees: 21,670

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 13 analysts
0
News positive %
of 9 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2023] → 6 (+2) [Q1 2024]

21% more first-time investments, than exits

New positions opened: 105 | Existing positions closed: 87

18% more capital invested

Capital invested by funds: $17.7B [Q4 2023] → $21B (+$3.26B) [Q1 2024]

2% more funds holding

Funds holding: 760 [Q4 2023] → 778 (+18) [Q1 2024]

7% more repeat investments, than reductions

Existing positions increased: 291 | Existing positions reduced: 271

0.86% more ownership

Funds ownership: 84.32% [Q4 2023] → 85.19% (+0.86%) [Q1 2024]

41% less call options, than puts

Call options by funds: $288M | Put options by funds: $489M

Research analyst outlook

13 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$225
17%
downside
Avg. target
$326
20%
upside
High target
$400
47%
upside

13 analyst ratings

positive
62%
neutral
31%
negative
8%
Evercore ISI Group
Elizabeth Anderson
11%upside
$300
Outperform
Maintained
10 Jun 2024
Morgan Stanley
Erin Wright
33%upside
$360
Overweight
Maintained
25 Apr 2024
Piper Sandler
Jason Bednar
38%upside
$375
Overweight
Reiterated
25 Apr 2024
Baird
Jeff Johnson
36%upside
$370
Outperform
Maintained
25 Apr 2024
Stifel
Jonathan Block
47%upside
$400
Buy
Maintained
18 Apr 2024

Financial journalist opinion

Based on 9 articles about ALGN published over the past 30 days